EQ
Price:
$0.711
Market Cap:
$25.19M
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointesti...[Read more]
Industry
Biotechnology
IPO Date
2018-10-12
Stock Exchange
NASDAQ
Ticker
EQ
According to Equillium, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.92. This represents a change of -97.74% compared to the average of -262.34 of the last 4 quarters.
The mean historical PE Ratio of Equillium, Inc. over the last ten years is -18.07. The current -5.92 PE Ratio has changed 3.18% with respect to the historical average. Over the past ten years (40 quarters), EQ's PE Ratio was at its highest in in the June 2024 quarter at 12.78. The PE Ratio was at its lowest in in the September 2024 quarter at -1052.61.
Average
-18.07
Median
-2.79
Minimum
-108.03
Maximum
-0.33
Discovering the peaks and valleys of Equillium, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 467.22%
Maximum Annual PE Ratio = -0.33
Minimum Annual Increase = -93.05%
Minimum Annual PE Ratio = -108.03
Year | PE Ratio | Change |
---|---|---|
2023 | -1.88 | 467.22% |
2022 | -0.33 | -88.09% |
2021 | -2.79 | -23.84% |
2020 | -3.66 | 59.30% |
2019 | -2.30 | -69.41% |
2018 | -7.51 | -93.05% |
The current PE Ratio of Equillium, Inc. (EQ) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.67
5-year avg
-2.19
10-year avg
-18.07
Equillium, Inc.’s PE Ratio is less than Lyra Therapeutics, Inc. (-0.13), less than HOOKIPA Pharma Inc. (-0.62), less than LianBio (-0.75), less than Jasper Therapeutics, Inc. (-5.21), less than Cingulate Inc. (-0.00), less than SAB Biotherapeutics, Inc. (-0.64), less than Anebulo Pharmaceuticals, Inc. (-4.78), less than Cadrenal Therapeutics, Inc. Common Stock (-2.18), less than Monopar Therapeutics Inc. (-0.54), less than Spero Therapeutics, Inc. (21.41), less than Bolt Biotherapeutics, Inc. (-0.34), greater than Coherus BioSciences, Inc. (-279.06), greater than Gracell Biotechnologies Inc. (-29.05), less than Neoleukin Therapeutics, Inc. (-5.86), less than Ikena Oncology, Inc. (-1.38), less than Werewolf Therapeutics, Inc. (-1.34), greater than Edgewise Therapeutics, Inc. (-24.30), less than Quoin Pharmaceuticals, Ltd. (-0.33), less than Pasithea Therapeutics Corp. (-0.00), less than aTyr Pharma, Inc. (-2.33), greater than Trevi Therapeutics, Inc. (-6.63), less than Cue Biopharma, Inc. (-1.17), less than AN2 Therapeutics, Inc. (-0.66), less than BioAtla, Inc. (-0.93),
Company | PE Ratio | Market cap |
---|---|---|
-0.13 | $12.37M | |
-0.62 | $20.76M | |
-0.75 | $34.47M | |
-5.21 | $330.78M | |
-0.00 | $15.42M | |
-0.64 | $28.89M | |
-4.78 | $37.86M | |
-2.18 | $24.86M | |
-0.54 | $106.08M | |
21.41 | $63.24M | |
-0.34 | $22.14M | |
-279.06 | $125.58M | |
-29.05 | $989.87M | |
-5.86 | $8.20M | |
-1.38 | $82.52M | |
-1.34 | $84.67M | |
-24.30 | $3.05B | |
-0.33 | $2.95M | |
-0.00 | $3.93M | |
-2.33 | $131.12M | |
-6.63 | $223.68M | |
-1.17 | $64.62M | |
-0.66 | $39.99M | |
-0.93 | $75.90M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Equillium, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Equillium, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Equillium, Inc.'s PE Ratio?
How is the PE Ratio calculated for Equillium, Inc. (EQ)?
What is the highest PE Ratio for Equillium, Inc. (EQ)?
What is the 3-year average PE Ratio for Equillium, Inc. (EQ)?
What is the 5-year average PE Ratio for Equillium, Inc. (EQ)?
How does the current PE Ratio for Equillium, Inc. (EQ) compare to its historical average?